ExodusPoint Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

ExodusPoint Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$148K	Sell	13,293 -9,108	-41%	-$115K	﹤0.01%	1411
2025 Q4	$372K	Sell	22,401 -48,874	-69%	-$698K	﹤0.01%	1253
2025 Q3	$839K	Buy	71,275 +56,129	+371%	+$579K	0.01%	1024
2025 Q2	$145K	Sell	15,146 -64,165	-81%	-$355K	﹤0.01%	1341
2025 Q1	$497K	Buy	+79,311	New	+$482K	﹤0.01%	1114
2024 Q4	–	Sell	-69,282	Closed	-$1.25M	–	1931
2024 Q3	$1.25M	Buy	+69,282	New	+$968K	0.01%	907
2023 Q4	–	Sell	-17,008	Closed	-$176K	–	1920
2023 Q3	$176K	Buy	+17,008	New	+$233K	﹤0.01%	1541
2021 Q2	–	Sell	-7,534	Closed	-$283K	–	2695
2021 Q1	$283K	Buy	+7,534	New	+$315K	﹤0.01%	1716
2020 Q2	–	Sell	-18,765	Closed	-$485K	–	1965
2020 Q1	$485K	Buy	+18,765	New	+$627K	0.03%	501

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

ExodusPoint Capital Management's PHAT Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Phathom Pharmaceuticals (PHAT) stake by 41% in Q1 2026, selling an estimated $115K and leaving 13,293 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #1411.

ExodusPoint Capital Management first reported a position in PHAT in Q1 2020 and has held it in 9 quarters since. The position peaked at $1.25M in Q3 2024. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

ExodusPoint Capital Management held 13,293 shares of Phathom Pharmaceuticals worth $148K as of Q1 2026.
ExodusPoint Capital Management sold 9,108 Phathom Pharmaceuticals shares in Q1 2026, an estimated $115K.
Phathom Pharmaceuticals made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1411 holding.
ExodusPoint Capital Management first reported a position in Phathom Pharmaceuticals in Q1 2020 and has held it in 9 quarters since.
ExodusPoint Capital Management's Phathom Pharmaceuticals position peaked at $1.25M in Q3 2024.
174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.